Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

🧠 Standard of Care & Symptoms

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an acquired, immune-mediated disorder of the peripheral nervous system leading to progressive demyelination.

• Presentation: Symmetric muscle weakness, sensory ataxia, and hyporeflexia.
  • Motor Weakness: Affects both proximal and distal muscles symmetrically. Patients experience difficulty rising from a chair or walking (proximal) as well as difficulty buttoning shirts or turning keys (distal).
  • Sensory Deficits: Numbness, paresthesias, and a loss of vibration and position sense, leading to sensory ataxia (clumsiness, unsteady gait, and positive Romberg sign).
  • Reflex Changes: General reduction or complete absence of deep tendon reflexes (areflexia).
• Clinical Course: Symptoms must progressively worsen or fluctuate over a period of **at least 8 weeks** to distinguish CIDP from acute inflammatory demyelinating polyneuropathy (AIDP, the classic form of Guillain-Barré syndrome).

🧬 Diagnostics & Paranodal Autoimmunity

Diagnosis is established using electrodiagnostic criteria, cerebrospinal fluid evaluation, and autoimmune serology to identify specific antibody-mediated variants.

• Nerve Conduction Studies (NCS): Show pathognomonic demyelinating features:
  • Prolonged distal motor latencies and reduced conduction velocity.
  • Partial conduction block and abnormal temporal dispersion of motor action potentials.
  • Marked prolongation or absence of F-wave latencies.
• Cerebrospinal Fluid (CSF) Analysis: Demonstrates **albuminocytologic dissociation** (elevated CSF protein level, often > 100 mg/dL, with a normal white blood cell count of < 10 cells/μL).

Nodal & Paranodal Autoimmune Targets

CIDP pathogenesis is characterized by specific antibodies targeting molecular structures at the Node of Ranvier:

• Paranodal IgG4 Autoantibodies: Approximately 10% of LEMS and demyelinating neuropathy patients present with specific IgG4 antibodies targeting nodal/paranodal proteins:
  • Neurofascin-155 (NF155): Autoantibodies against NF155 disrupt the paranodal junction. These patients present with a distinct clinical phenotype: younger onset, severe postural tremor, marked sensory ataxia, and a poor response to standard IVIG.
  • Contactin-1 (CNTN1) & Caspr1: Target proteins that anchor myelin loops to the axon. Associated with acute, aggressive motor decline and sensory ataxia.
• Myelin Sheath Demyelination: The autoimmune attack disrupts the junctional loops of myelin, causing myelin retraction, exposing voltage-gated potassium channels, and preventing salutatory conduction down the peripheral nerve.

💊 IVIG, Corticosteroids & Rituximab

Therapy focuses on suppressing the inflammatory attack on peripheral myelin, restoring nerve conduction, and preventing secondary axonal degeneration.

First-Line Immunotherapy

• Intravenous Immunoglobulin (IVIG): Enhances antibody clearance and neutralizes pathogenic cytokines. Administered as a loading dose (2 g/kg) followed by maintenance infusions every 3 to 4 weeks.
• Systemic Corticosteroids: High-dose oral Prednisone or pulsed intravenous Methylprednisolone. Provides comparable efficacy to IVIG but requires long-term taper management.
• Plasma Exchange (Plasmapheresis): Diversion of blood to filter out circulating antibodies, used as an acute treatment for severe flares.

Targeted Biologic Therapy (IgG4-Positive Patients)

• Rituximab (Anti-CD20 Monoclonal Antibody): Depletes B cells. **Rituximab is the first-line therapy for patients positive for anti-NF155 or anti-CNTN1 IgG4 antibodies**, as these paranodal IgG4 antibodies do not bind complement and are highly resistant to standard IVIG or steroids.

🔬 Active Clinical Trials

Clinical trials are currently evaluating subcutaneous immunoglobulin (SCIG) for home administration, selective FcRn blockers to accelerate IgG4 clearance, and complement inhibitors for classic CIDP.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with CIDP, follow these clinical steps:

1. Confirm Nerve Conduction Studies: Document that your nerve velocities show demyelination (delayed conduction) rather than primary nerve axon loss (axonopathy).
2. Test for anti-NF155 and anti-CNTN1 IgG4 Antibodies: Ensure these are checked; if positive, request Rituximab rather than wasting months on ineffective IVIG.
3. Schedule a Lumbar Puncture: Verify elevated CSF protein levels without white blood cells to support the autoimmune diagnosis.
4. Initiate IVIG or Prednisone: Start therapy immediately to stop demyelination and prevent irreversible nerve damage (axonal loss).

❓ Patient FAQ

Q: How does CIDP differ from Guillain-Barré Syndrome (GBS)?
A: Both are demyelinating autoimmune nerve diseases, but their timelines are completely different. GBS is an **acute** illness that peaks within 2 to 4 weeks, often following a viral infection, and most patients recover fully over months. CIDP is a **chronic** condition where symptoms progress slowly or relapse over at least 8 weeks, requiring long-term maintenance immune therapies to prevent permanent weakness.

Q: What are anti-NF155 and anti-CNTN1 antibodies? Why do they matter?
A: These are autoantibodies that target the "paranode"—the region where the myelin sheath anchors to the nerve axon. Patients who have these specific IgG4 antibodies (about 10% of CIDP cases) have a unique variant of the disease that often causes severe tremors, coordinate imbalance (ataxia), and is highly resistant to standard treatments like IVIG and steroids. If you test positive for these, your neurologist will likely recommend starting Rituximab early to achieve remission.